Literature DB >> 30006990

Donor lymphocyte infusion leads to diversity of specific T cell responses and reduces regulatory T cell frequency in clinical responders.

Susanne Hofmann1,2, Michael Schmitt1, Marlies Götz2, Hartmut Döhner2, Markus Wiesneth3, Donald Bunjes2, Jochen Greiner2,4.   

Abstract

T cell responses against malignant cells play a major role in maintaining remission and prolonging overall survival in patients after allogeneic stem cell transplantation and donor lymphocyte infusion (DLI) due to graft-versus-leukemia effect. For better characterization of the T cell responses, we assessed frequency and diversity of leukemia-associated antigen (LAA)-specific cytotoxic T cells using ELISpot and pMHC multimer assays and analyzed the frequency of regulatory T cells (Treg) as well as cytokine profiles before/after DLI. The data were correlated to the clinical course of patients. Significantly more LAA-derived T cell epitopes (p = 0.02) were recognized in clinical responders (R) when compared to nonresponders (NR). In addition, pMHC multimer-based flow cytometry showed a significantly higher frequency of LAA-specific T cells in R versus NR. The frequency of Treg in R decreased significantly (p = 0.008) while keeping stable in NR. No differences in T cell subset analysis before/after DLI were revealed. Clinical responders were correlated to specific immune responses and all clinical responders showed an increase of specific immune responses after DLI. Cytokine assays using enzyme-linked immunosorbent assay showed a significant increase of IL-4 after DLI. Taken together, an increase of specific CTL responses against several LAA after DLI was detected. Moreover, this study suggests that enhanced LAA diversity in T cell responses as well as decreasing numbers of Treg contribute to clinical outcome of patients treated with DLI.
© 2018 UICC.

Entities:  

Keywords:  cytotoxic T cell responses; donor lymphocyte infusion; leukemia-associated-antigens

Mesh:

Year:  2018        PMID: 30006990     DOI: 10.1002/ijc.31753

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  Allogeneic Tumor Antigen-Specific T Cells for Broadly Applicable Adoptive Cell Therapy of Cancer.

Authors:  Zaki Molvi; Richard J O'Reilly
Journal:  Cancer Treat Res       Date:  2022

Review 2.  Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients.

Authors:  Jochen Greiner; Marlies Götz; Donald Bunjes; Susanne Hofmann; Verena Wais
Journal:  J Clin Med       Date:  2019-12-23       Impact factor: 4.241

3.  Non-Ablative Chemotherapy Followed by HLA-Mismatched Allogeneic CD3+ T-Cells Infusion Causes An Augment of T-Cells With Mild CRS: A Multi-Centers Single-Arm Prospective Study on Elderly Acute Myeloid Leukemia and int-2/High Risk Myelodysplastic Syndrome Patients.

Authors:  Yan Huang; Minghua Hong; Zhigang Qu; Weiyan Zheng; Huixian Hu; Linjie Li; Ting Lu; Ying Xie; Shuangwei Ying; Yuanyuan Zhu; Lizhen Liu; Weijia Huang; Shan Fu; Jin Chen; Kangli Wu; Mingsuo Liu; Qiulian Luo; Yajun Wu; Fang He; Jingcheng Zhang; Junyu Zhang; Yu Chen; Minlei Zhao; Zhen Cai; He Huang; Jie Sun
Journal:  Front Oncol       Date:  2021-10-13       Impact factor: 6.244

Review 4.  Increasing Role of Targeted Immunotherapies in the Treatment of AML.

Authors:  Jochen Greiner; Marlies Götz; Verena Wais
Journal:  Int J Mol Sci       Date:  2022-03-18       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.